ESH 2017 | The problem of treating AML with CD123-targeting drugs
As diseases mutate our knowledge of them increases. In this interview, Prof. John DiPersio, MD, PhD from Washington University School of Medicine, Washington, WA explains how the low number of mutations in acute myeloid leukemia affects treatment and research. Prof. DiPersio also touches upon how he utilizes the shared antigen CD123 in his research, its difficulties and why bispecific therapies are useful. This interview was recorded at the International Conference on Acute Myeloid Leukaemia 2017, Estoril, Portugal by the European School of Haematology (ESH).
Get great new content delivered to your inboxSign up